Targeting protein lipidation in disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Fatty acids and/or isoprenoids are covalently attached to a variety of disease-related proteins. The distinct chemical properties of each of these hydrophobic moieties allow lipid modification to serve as a mechanism to regulate protein structure, localization and function. This review highlights recent progress in identifying inhibitors of protein lipidation and their effects on human disease. Myristoylation inhibitors have shown promise in blocking the action of human pathogens. Although inhibitors that block prenylation of Ras proteins have not yet been successful for cancer treatment, they may be efficacious in the rare premature aging syndrome progeria. Agents that alter the palmitoylation status of Ras, Wnt and Hh proteins have recently been discovered, and represent the next generation of potential chemotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 3×
“Third, the lack of correlation between response to FTIs and Ras mutational status, whether measured in cells, mouse xenografts or human patients [14], implies that other targets for FTIs are involved.”
BackgroundTrafficking and signaling by fatty-acylated and prenylated proteins
Resh, M. D. (2006) · Nature Chemical Biology · doi:10.1038/nchembio834 · Cited by 521
Self-citationSiegel, G., Obernosterer, G., Fiore, R., Oehmen, M., Bicker, S., Christensen, M., Khudayberdiev, S., Leuschner, P. F., Busch, C. J. L., Kane, C., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1876 · Cited by 500
Castro, A. F., Rebhun, J. F., Clark, G. J., & Quilliam, L. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300226200 · Cited by 381 · cited 1×
“Farnesylation of Rheb is required for its ability to stimulate mTOR [24], a protein kinase involved in regulation of normal and malignant cell growth.”
BackgroundWinter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., & Casey, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408107102 · Cited by 178 · cited 2×
“This modification plays an important role in regulating the Wnt signaling pathways, which are crucial for regulating cell growth Palmitoyl acyltransferase (PAT) a family of enzymes that catalyzes attachment of palmitate and other long chain fatty acids to protein targets Porcn a member of the MBOAT family implicated i…”
BackgroundThe Lipid Raft-Anchored Adaptor Protein Cbp Controls the Oncogenic Potential of c-Src
Oneyama, C., Hikita, T., Enya, K., Dobenecker, M.-W., Saito, K., Nada, S., Tarakhovsky, A., & Okada, M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.026 · Cited by 116
Farnesyltransferase inhibitors: where are we now?
Tsimberidou, A. M., Chandhasin, C., & Kurzrock, R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.535516 · Cited by 39 · cited 1×
“Over the past decade, intensive efforts have been devoted to developing FTase inhibitors (FTIs) as anti-cancer agents [14, 15].”
Background
Cited by
Cellular Fatty Acid Metabolism and Cancer
Currie, E., Schulze, A., Zechner, R., Walther, T. C., & Farese, R. V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.017 · Cited by 2,123
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Metabolic Signaling in Fuel-Induced Insulin Secretion
Prentki, M., Matschinsky, F. M., & Madiraju, S. R. M. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.018 · Cited by 548
“FA-CoA modulates signaling effectors in various cell types and serves as substrate for protein acylation (Corkey et al., 2000; Resh, 2012).”
BackgroundTargeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox, A. D., Der, C. J., & Philips, M. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3214 · Cited by 351
Wnt/β-catenin signalling in prostate cancer
Kypta, R. M., & Waxman, J. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.116 · Cited by 275
Metadata
- Authors
- Resh, M. D.
- Venue
- Trends in Molecular Medicine
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 18
- Issue
- 4
- Pages
- 206-214
- ISSN
- 1471-4914 (ISSN-L)
- OpenAlex
- W1986698046
- Cited by
- 139
- References
- 9
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.